ID: ALA3407866

Max Phase: Preclinical

Molecular Formula: C11H6Cl2N2O2

Molecular Weight: 269.09

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C(O)c1cc(-c2ccc(Cl)c(Cl)c2)ncn1

Standard InChI:  InChI=1S/C11H6Cl2N2O2/c12-7-2-1-6(3-8(7)13)9-4-10(11(16)17)15-5-14-9/h1-5H,(H,16,17)

Standard InChI Key:  FPVPSYCVUOIXCH-UHFFFAOYSA-N

Associated Targets(Human)

Kynurenine 3-monooxygenase 379 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Kynurenine 3-monooxygenase 34 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Kynurenine 3-monooxygenase 207 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 269.09Molecular Weight (Monoisotopic): 267.9806AlogP: 3.15#Rotatable Bonds: 2
Polar Surface Area: 63.08Molecular Species: ACIDHBA: 3HBD: 1
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 0.76CX Basic pKa: 5.25CX LogP: 1.70CX LogD: 0.00
Aromatic Rings: 2Heavy Atoms: 17QED Weighted: 0.91Np Likeness Score: -1.20

References

1. Toledo-Sherman LM, Prime ME, Mrzljak L, Beconi MG, Beresford A, Brookfield FA, Brown CJ, Cardaun I, Courtney SM, Dijkman U, Hamelin-Flegg E, Johnson PD, Kempf V, Lyons K, Matthews K, Mitchell WL, O'Connell C, Pena P, Powell K, Rassoulpour A, Reed L, Reindl W, Selvaratnam S, Friley WW, Weddell DA, Went NE, Wheelan P, Winkler C, Winkler D, Wityak J, Yarnold CJ, Yates D, Munoz-Sanjuan I, Dominguez C..  (2015)  Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.,  58  (3): [PMID:25590515] [10.1021/jm501350y]
2. Amin SA, Adhikari N, Jha T, Gayen S..  (2016)  First molecular modeling report on novel arylpyrimidine kynurenine monooxygenase inhibitors through multi-QSAR analysis against Huntington's disease: A proposal to chemists!,  26  (23): [PMID:27838184] [10.1016/j.bmcl.2016.10.058]
3. Ahamad S, Bhat SA..  (2022)  The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington's Disease.,  65  (24.0): [PMID:36490325] [10.1021/acs.jmedchem.2c00799]

Source